Shares of Cardiff Oncology, Inc. (CRDF) are up 8% on Wednesday following the company's announcement of positive clinical data from its ongoing trials on metastatic pancreatic ductal adenocarcinoma (mPDAC) and small cell lung cancer (SCLC) with onvansertib monotherapy and combination therapy.
Cardiff Oncology (CRDF) Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Cardiff Oncology, Inc. (NASDAQ: CRDF) shares are trading higher Tuesday after-hours after the company announced clinical data in pancreatic cancer and small cell lung cancer, including single-agent activity
Pancreatic Cancer Program
- Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical controls with ORR of 19% and mPFS of 5.0.
Pancreatic Cancer Program - Pancreatic cancer Phase 2 trial of onvansertib + SoC in the second-line setting demonstrated greater efficacy vs. historical.